Jan 24, 2024, 22:30
Raffaele Colombo: Evoke-01 study of sacituzumab govitecan (SG) did not meet its primary overall survival goal in patients with NSCLC
Raffaele Colombo, Principal Scientist at Zymeworks, shared on X:
“Evoke-01 study of sacituzumab govitecan (SG) did not meet its primary overall survival goal in patients with NSCLC
‘A numerical improvement in OS favoring SG was observed’
‘A more than 3-month difference in OS favoring SG was observed in a sub-group'”
Read further.
Source: Raffaele Colombo/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 14, 2024, 09:31
Nov 14, 2024, 09:26
Nov 14, 2024, 09:21
Nov 14, 2024, 09:15
Nov 14, 2024, 00:19